Our burgeoning health tech firm is tapping into an eight-figure investment war chest to deliver rapid European growth.

Here at Emblation, we are expanding our pioneering microwave treatment, following an injection of capital from specialist healthcare investors, which has already seen staff numbers increase by 50% and ongoing fit out of our new HQ in Stirling.

Since launching a radical new treatment device for the podiatry sector in 2016, we have enjoyed major success with thousands of practitioners using our microwave technology across the UK, US, Canada and Australia.

Founders Gary Beale and Eamon McErlean – who met during post-graduate studies at Heriot Watt University in Edinburgh – say that having weathered the pandemic, their focus is now on expanding in Europe, where our Swift® therapy is less-widely used.

Gary, CEO of Emblation, said: "European medical distributors, podiatrists and dermatologists are keen to get their hands on Swift&reg, which has met rave reviews from experts across existing markets."

Major new distribution deals, clinical partnerships and other opportunities are close to completion across mainland Europe – spearheaded by recent appointments in Germany, Benelux, France, Switzerland and Greece as well as further afield including Israel and UAE.

Gary added: "One of our key focuses over the next year is to get a serious foothold in Europe and we are making impressive progress on multiple fronts. The commercial team are working tirelessly on making this happen.

"When we recently secured major investment, the goal was to expand into new territories and that means mainland Europe. The success of Swift in the UK, US, Canada and Australia gives us a fantastic platform for this next phase of the company’s growth.

"We are incredibly proud to be a Scottish firm flying the flag in Europe and overcoming the many hurdles posed by both Brexit and the ongoing COVID pandemic. It is a huge testament to the team who have worked so hard to get us here. It is a highly exciting time in Emblation’s evolution."

Swift, which enables medical experts to resolve persistent common and plantar warts (verrucae) with a simple microwave treatment has won widespread praise and recognition within both the medical and technology arena.

As part of our growth, Emblation has grown our research and development capability to build on promising early results which could result in breakthroughs in the treatment of skin cancers and pre-cancers as well.

Dermatologists are also eager to see Swift rolled out for treatment of a wider range of skin conditions, including pre-cancerous skin lesions where initial studies have shown excellent outcomes.

Established in 2008, Emblation secured major second round investment from Apposite Capital in May 2021 and we are currently fitting out a purpose-built, 20,000 sq ft headquarters located at Castle Business Park against the idyllic backdrop of Stirling Castle, due to open later this year.

Currently based in Alloa, headcount at our clinical technology firm has more than doubled in the last 12 months and there are plans to more than double again over the next 18 months to support the expansion strategy and international brand roll-out.